Evaluation of prognostic value of lncRNA BANCR in tumor patients: A systematic review and meta-analysis.

PURPOSE

Long non-coding RNA (lncRNA) BANCR is reported to be upregulated in many tumors. Nevertheless, the potential value of BANCR in tumor prognosis is unclear, which is mainly explored in this study.

METHODS

Articles published before January 1, 2019 on the correlation between BANCR and prognosis, lymph node metastasis and distant metastasis were searched for in PubMed, Embase, Cochrane Library and Web of Science and relevant data were extracted. The correlation between the expression of BANCR and tumor prognosis using four survival indicators, including overall survival (OS), disease-free survival (DFS), relapse-free survival (RFS) and progression-free survival (PFS)), lymph node metastasis and distant metastasis was analyzed by calculating hazard ratio (HR), odds ratio (OR) and 95%CI. A heterogeneity test was performed on the selected articles, and the combined effect size, HR, OR and 95%CI were calculated using STATA 12.0 software.

RESULTS

A total of 11 articles including 1240 tumor patients were included in this meta-analysis. OS was shorter in tumor patients with high BANCR expression (HR=1.58, 95%CI:1.10-2.26), whereas RFS, DFS and PFS were not shorter compared with low BANCR expression (HR=1.26, 95%CI: 0.50-3.18). Moreover, regression analysis revealed that a high level of BANCR was correlated with lymph node metastasis (OR=1.61, 95%CI: 1.24-2.10) and distant metastasis (OR=2.22, 95%CI: 1.35-3.65).

CONCLUSIONS

BANCR overexpression was closely correlated with poor overall survival, lymph node metastasis and distant metastasis. Our conclusion still needs to be further verified in a multi-hospital trial using a large sample size.